Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,650 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,492)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03661567 | Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer | terminated | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer | terminated | Phase 3 | 5 | Regeneron PharmaceuticalsINDUSTRY | 3 | Nov 16, 2022 |
| clinicaltrials |
| NCT04155008 | Nutrition and Pharmacological Algorithm for Oncology Patients Study | terminated | Phase 4 | 1 | Montefiore Medical CenterOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05032352 | Predictive Assay for Decision Making in Adjuvant Therapy(PADMA) | terminated | — | 55 | Insight Molecular DiagnosticsINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT03784599 | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC(TRAEMOS) | terminated | Phase 2 | 28 | The Netherlands Cancer InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | terminated | Phase 1 | 30 | AmgenINDUSTRY | 5 | Nov 8, 2022 | clinicaltrials |
| NCT03430063 | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | terminated | Phase 2 | 28 | Regeneron PharmaceuticalsINDUSTRY | 9 | Nov 3, 2022 | clinicaltrials |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | terminated | Phase 2 | 22 | Ludwig Institute for Cancer ResearchOTHER | 5 | Oct 25, 2022 | clinicaltrials |
| NCT04634110 | Brigatinib Before Brain Irradiation Trial (B3i Trial) | terminated | Phase 2 | 1 | University of Colorado, DenverOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | terminated | Phase 1 | 3 | University of California, San FranciscoOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT02688166 | Cardiac MRI Biomarker Testing (GCC 1618) | terminated | — | 6 | University of Maryland, BaltimoreOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT04398199 | Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients | terminated | Phase 2 | 1 | Wake Forest University Health SciencesOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | terminated | Phase 1 | 9 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC(KEAPSAKE) | terminated | Phase 2 | 40 | Calithera Biosciences, IncINDUSTRY | 1 | Sep 21, 2022 | clinicaltrials |
| NCT04862195 | Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment | terminated | N/A | 31 | Blue Note TherapeuticsINDUSTRY | 1 | Sep 13, 2022 | clinicaltrials |
| NCT00754364 | Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients | terminated | Phase 2 | 108 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02967133 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | terminated | Phase 2 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy(NAC-PNP) | terminated | N/A | 69 | Rijnstate HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | terminated | Phase 2 | 9 | Helix BioPharma CorporationINDUSTRY | 2 | Aug 12, 2022 | clinicaltrials |
| NCT02400814 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 27 | Megan Daly, MDOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | terminated | Phase 2 | 19 | WindMIL TherapeuticsINDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04560686 | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02856581 | Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes | terminated | Phase 3 | 23 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT03321747 | Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung | terminated | Phase 1 | 13 | Indiana UniversityOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 28 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 12, 2022 | clinicaltrials |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | terminated | Phase 2 | 3 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03209128 | Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala(IPC) | terminated | — | 11 | Centre Francois Baclesse, LuxembourgOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | terminated | Phase 2 | 21 | University of WashingtonOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | terminated | Phase 1 | 2 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | terminated | Phase 1 | 10 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03904108 | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | terminated | Phase 2 | 3 | ROGER S KERESZTES MDOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT02385812 | Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma | terminated | Phase 2 | 200 | University of CalgaryOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy | terminated | Phase 3 | 8 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | terminated | Phase 4 | 81 | Radboud University Medical CenterOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT01067144 | Stanford Accelerated Recovery Trial (START) | terminated | Phase 3 | 422 | Stanford UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | terminated | — | 8 | Mayo ClinicOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 22 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) | terminated | Phase 3 | 130 | Sumitomo Pharma Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | terminated | Phase 1 | 1 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 1 | 16 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Nov 30, 2022source: clinicaltrials